CHEK2 and breast carcinoma: The authors concluded that 6.8% of the (European) breast cancer patients and 2.0% of the controls had protein truncating variants in the genes associated with breast cancer risk and 2.2% of the patients and 1.4% of the controls had missense variants in CHEK2 [15].